The Role of mTOR Inhibitors after Liver Transplantation for Hepatocellular Carcinoma

Round 1

Reviewer 1 Report

Very good paper,

well written, comprehensive, important for readers from the field, correct.

I have only three remarks:

1) describe in appropriate detail the risk factors (portrait of the patient) for de novo malignancy (line 264-5) ;

2) I recommend to reconsider balance between volume of the text devoted TO THE topic (HCC), and volume devoted to the meticulous descriptions of topics under 6.2-7.4. They are boring to the reader teased by headline.

3) one more English spell check   

As above, 

plus

line 133, sentence "Considering..." should be re-written for cllear meaning

line 154, replace "esteemed" for another, more appropriate synonym

Author Response

Please see the attachment

Author Response File: Author Response.docx

Reviewer 2 Report

The present manuscript reviewed the clinical and pharmaceutical roles of mTOR inhibitors for the HCC patients after the treatment of liver transplantation. The inhibition of mTOR has multimodal effects on prolonging the survival of patients who undergo liver transplantation. The inhibition of mTOR can induce the immunosuppressive effect which act an alternative approach to conventional calcineurin inhibitors, the suppression of tumor regrowth by inhibiting PI3K-AKT-mTOR pathway. The adverse effects of the treatment of mTOR inhibitors are also mentioned. The reviewer considers that the present review manuscript is well-constructed and the number of references is sufficient. While the present manuscript can be accepted, the reviewer expects to add some comments regarding the current problems of therapeutic approach by mTOR inhibitors and the strategies to solve them.

Author Response

Please see the attachment

Author Response File: Author Response.docx